Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines

Laboratory Investigation

Volumn 74, Issue 2, 1996, Pages 406-421

  Afzal, Saliha ^a   Lalani, El Nasir ^a   Foulkes, William D ^c   Boyce, Byron ^b   Tickle, Simon ^b   Cardillo, Maria Rosaria ^a   Baker, Terry ^b   Pignatelli, Massimo ^a   Stamp, Gordon W H ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UCB PHARMA   (Belgium)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; GELATINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; BINDING SITE; CANCER INVASION; CELL SURFACE; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

AMIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BIOTIN; CARCINOMA; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MICE; OVARIAN NEOPLASMS; PROTEASE INHIBITORS; PROTEINS; TISSUE DISTRIBUTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR CELLS, CULTURED;

EID: 0030030957     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Afzal S, Lalani E-N, Baker T, Boyce B, Docherty A, Pignatelli M, Stamp GWH (1994). Membrane localisation of activated gelatinases in adenocarcinomas. J Path 172:101A.
2. Alessandro R, Minafra S, Pucci MI, Onisto M, Garbisa S, Melchiori A, Tetlow L, Woolley DE (1993). Metalloproteinase and TIMP expression by the human breast carcinoma cell line 8701-BC. Int J Cancer 55:250-255.
3. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, and Stetler-Stevenson WG (1991). Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775-779.
4. Akiyama SK, Larjava H, and Yamada KM (1990). Differences in the biosynthesis and localization of the fibronectin receptor in normal and transformed cultured human cells. Cancer Res 50:1601-1607.
5. Azzam HS, Arand G, Lippman ME, and Thompson EW (1993). Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758-1764.
6. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, and Smith HS (1994). The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54:861-866.
7. Bonfil RD, Medina PA, Gomez DE, Farias E, Lazarowski A, Lucero GM, Meiss RP, and Bustuoabad OD (1992). Expression of gelatinase/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion. Clin Exp Metastasis 10:211-220.
8. Brown PD, Levy AT, Margulies IM, Liotta LA, and Stetler-Stevenson WG (1990). Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 50:6184-6191.
9. Campo E, Merino MJ, Liotta L, Neumann R, and Stetler-Stevenson WG (1992a). Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 23:1395-1401.
10. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, and Liotta LA (1992b). Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16:500-507.
11. Cao J, Sato H, Takino T, and Seiki M (1995). The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for progelatinase A activation. J Biol Chem 270:801-805.
12. Cockett MI, Birch ML, Murphy G, Hart IR, and Docherty AJP (1994). Metalloproteinase domain structure, cellular invasion and metastasis. Biochem Soc Trans 22:55-57.
13. Danen EH, Ten Berge P, Van Muijen GN, Van 't Hof Grootenboer AE, Brocker EB, and Ruiter DJ (1994). Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 24:249-256.
14. Davies B, Brown PD, East N, Crimmin MJ, and Balkwill FR (1993). A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087-2091.
15. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, and Balkwill FR (1993). Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67:1126-1131.
16. De Clerck YA, Perez N, Shimada H, Boone TC, Langley KE, and Taylor SM (1992). Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701-708
17. Emonard HP, Remacle AG, Noel AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM (1992). Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase. Cancer Res 52:5845-5848.
18. Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ, and Trowsdale J (1993). Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 67:551-559.
19. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, and He C (1989). Human 72 kDa type IV collagenase forms a complex with a tissue inhibitor of metalloproteinase designated TIMP-2. Proc Natl Acad Sci 86:8207-8211.
20. Gordon JL, Drummond AH, and Galloway WA (1993). Metalloproteinase inhibitors as therapeutics. Clin Exp Rheumatol 11:S91-S94.
21. Hart IR and Saini A (1992). Biology of tumour metastasis. Lancet 339:1453-1457.
22. Hendrix MJ, Wood WR, Seftor EA, Lotan D, Nakajima M, Misiorowski RL, Seftor RE, Stetler-Stevenson WG, Bevacqua SJ, Liotta LA, Sobel ME, Raza A, and Lotan R (1990). Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 50:4121-4130.
23. Hill PA, Murphy G, Docherty AJP, Hembry RM, Millican TA, Reynolds JJ, and Meikle MC (1994). The effects of selective inhibitors of matrix metalloproteinase (MMPs) and TIMP-1 in isolated osteoclasts. J Cell Sci 107:3055-3064.
24. Hoyhtya M, Fridman R, Komarek D, Porter JK, Stetler-Stevenson WG, Liotta LA, and Liang CM (1994). Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56:500-505.
25. Hsu SM, Raine L, and Fauger H (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29:577-580.
26. Kataoka H, De Castro R, Zucker S, and Biswas C (1993). Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 53:3154-3158.
27. Khokha R, Zimmer MJ, Graham CH, Lala PK, and Waterhouse P (1992). Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 84:1017-1022.
28. Khokha R (1994). Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86:299-304.
29. Kolkenbrock H, Hecker-Kia A, Orgel D, Ruppitsch W, and Ulbrich N (1994). Activity of ternary gelatinase A-TIMP-2-matrix metallo-proteinase complexes. Biol Chem Hoppe-Seyler 375:589-595.
30. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF, and Groom AC (1994). Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54:4791-4797.
31. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, and Stetler-Stevenson WG (1991). Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51:439-444.
32. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, and Shafie S (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68.
33. Liotta LA and Stetler-Stevenson WG (1991). Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51:5054s.
34. Lokeshwar BL, Selzer MG, Block NL, and Gunja SZ (1993). Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53:4493-4498.
35. Marshall BC, Santana A, Xu QP, Petersen MJ, Campbell EJ, Hoidal JR, and Welgus HG (1993). Metalloproteinases and tissue inhibitor of metalloproteinases in mesothelial cells. Cellular differentiation influences expression. J Clin Invest 91:1792-1799.
36. Matrisian LM (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121-125.
37. Matrisian LM (1992). The matrix-degrading metalloproteinases. Bioessays 14:455-463.
38. Monsky WL, Kelly T, Lin CY, Yeh Y, Stetler-Stevenson WG, Mueller SC, and Chen WT (1993). Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res 53:3159-3164.
39. Monteagudo C, Merino MJ, San JJ, Liotta LA, and Stetler-Stevenson WG (1990). Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 136:585-592.
40. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RJ, and Stack MS (1994). Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 56:552-559.
41. Murphy G and Docherty AJP (1992a). The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7:120-125.
42. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, and Docherty AJP (1991). The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30:8097-8102.
43. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, and Docherty AJP (1994). Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 269:6632-6636.
44. Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, and Docherty AJP (1992). The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J 283:637-641.
45. Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S, and Okuyama A (1994). Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer 58:730-735.
46. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, and Okada Y (1994). Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 81:69-77.
47. Naylor MS, Stamp GWH, Davies B, and Balkwill FR (1994). Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer. 58:50-56.
48. Nguyen Q, Willenbrock F, Cockett MI, O'Shea M, Docherty AJP, and Murphy G (1994). Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry 33: 2089-2095.
49. Niedbala MJ, Crickard K, and Bernacki RJ (1987). In vitro degradation of extracellular matrix by human ovarian carcinoma cells. Clin Exp Metastasis 5:181-197.
50. Noel AC, Polette M, Lewalle JM, Munaut C, Emonard HP, Birembaut P, and Foidart JM (1994). Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast-adenocarcinoma cells. Int J Cancer 56:331-336.
51. Okada A, Bellocq J-P, Rouyer N, Chenard M-P, Rio M-C, Chambon P, and Basset P (1995). Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci 92:2730-2734.
52. Okada Y, Nagase H, and Harris EJ (1986). A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem. 261:14245-14255.
53. Pignatelli M, Smith ME, and Bodmer WF (1990). Low expression of collagen receptors in moderate and poorly differentiated colorectal adenocarcinomas. Br J Cancer 61:636-638.
54. Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, and Stamp GWH (1993). Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 46:429-436.
55. Poulsom R, Pignatelli M, Steler-Stevenson WG, Liotta L, Wright P, Jeffery R, Longcroft J, Rogers L, and Stamp GWH (1992). Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. J Path 167S:150A.
56. Polette M, Clavel C, Birembaut P, and De Clerck YA (1993). Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract 189:1052-1057.
57. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remade A, Stetler-Stevenson WG, Birembaut P, and Foidart M (1994). Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch 424:641-645.
58. Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, and Tryggvason K (1992). Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52:1336-1341.
59. Pyke C, Ralfkiaer E, Tryggvason K, and Dano K (1993). Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359-365.
60. Ray JM and Stetler-Stevenson WG (1994). The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7:2062-2072.
61. Ries C and Petrides E (1995). Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe-Seyler 376:345-355.
62. Riordan F, Lalani E-N, Cardillo M, Baker T, Docherty A, Poulsom A, Pignatelli M, and Stamp GWH (1993). Expression of gelatinase A (72 kDa type IV collagenase), TIMP-2 and stromelysin in ovarian carcinomas. J Path 170:179.
63. Rucklidge GJ, Edvardsen K, and Bock E (1994). Cell-adhesion molecules and metalloproteinases: A linked role in tumour cell invasiveness. Biochem Soc Trans 22:63-68.
64. Ruoslahti E (1992). Control of cell motility and tumour invasion by extracellular matrix interactions. Br J Cancer 66:239-242.
65. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, and Seiki M (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65.
66. Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, and Hendrix MJ (1992). Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89:1557-1561.
67. Seftor RE, Seftor EA, Stetler-Stevenson WG, and Hendrix MJ (1993). The 72 kDa type IV collagenase is modulated via differential expression of alpha v beta 3 and alpha 5 beta 1 integrins during human melanoma cell invasion. Cancer Res 53:3411-3415.
68. Stetler-Stevenson WG, Krutzsch HC, and Liotta LA (1989). Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264:17374-17378.
69. Stetler-Stevenson WG, Liotta LA, and Kleiner DJ (1993). Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J 7:1434-1441.
70. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, and Goldberg GI (1995). Mechanism of cell surface activation of 72 kDa type IV collagenase. J Biol Chem 270:5331-5338.
71. Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, Pulyaeva H, Tamborlane JW, Tirgari R, Wapnir I, and Azzam H (1994). Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res and Treat 31:357-370.
72. Tryggvason K, Hoyhtya M, and Pyke C (1993). Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209-218.
73. Visscher DW, Hoyhytya M, Ottosen SK, Liang C-M, Sarkar FH, Crissman JD, and Fridman R (1994). Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59:339-344.
74. Wang X, Fu X, Brown PD, Crimmin MJ, and Hoffman RM (1994). Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726-4728.
75. Willenbrock F, Crabbe T, Slocombe PM, Sutton CW, Docherty AJP, Cockett MI, O'Shea M, Brocklehurst K, Phillips IR, and Murphy G (1993). The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A. Biochemistry 32:4330-4337.
76. Young TN, Pizzo SV, and Stack MS (1995). A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem 270:999-1002.
77. Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV, and Stack MS (1994). Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 170:1285-1296.